Limitations of employing antibody drug conjugates (ADCs) for targeting HIV infected cells as a strategy for hiv cure

• J. Strizki,
• D. Graham,
• M. Lu,
• G. Wu,
• M. Breslin,
• N. Davis,
• E. Escandon,
• L. Fayadat-Dilman,
• Y. Zheng,
• R. Barnard,
• R. Garbaccio,
• A. Manibusan,
• S. Bhowmik,
• D. Gately,
• Y. Sun,
• D. Gorman

Affiliations

J. Strizki

Merck Research Labs, West Point, PA, USA

D. Graham

Merck Research Labs, West Point, PA, USA

M. Lu

Merck Research Labs, West Point, PA, USA

G. Wu

Merck Research Labs, West Point, PA, USA

M. Breslin

Merck Research Labs, West Point, PA, USA

N. Davis

Palo Alto, CA, USA

E. Escandon

Palo Alto, CA, USA

L. Fayadat-Dilman

Palo Alto, CA, USA

Y. Zheng

Palo Alto, CA, USA

R. Barnard

Merck Research Labs, West Point, PA, USA

R. Garbaccio

Merck Research Labs, West Point, PA, USA

A. Manibusan

Ambrx, San Diego, CA, USA

S. Bhowmik

Ambrx, San Diego, CA, USA

D. Gately

Ambrx, San Diego, CA, USA

Y. Sun

Ambrx, San Diego, CA, USA

D. Gorman

Palo Alto, CA, USA